CliffBio
small molecule

INNOHEP

TINZAPARIN SODIUM

Loss of exclusivity—loss of exclusivity
CompanyLEO PHARMA AS

Drug detail

Brand nameINNOHEP
Active ingredientTINZAPARIN SODIUM
Strength20,000 IU/ML
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJuly 2000
Marketing statusDISCN

More from LEO PHARMA AS

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

INNOHEP patent cliff — loss of exclusivity — | CliffBio